Anavex Life Sciences Corp (AVXL)

[nidan7500]

Thanks hnbbadger1...Noted no contradictions with AVXL research published to date.


[quote]Increasing evidence has proved that the s1 receptor holds great potential as a biomarker for early AD diagnosis and progression and the monitoring of AD drug efficacy [49]. Hallmarks of human AD include progressive cognitive decline that follows chronic neuroinflammation and the emergence of hyperphosphorylated tau protein aggregates and Aß plaques [46], with all playing critical and perhaps interrelated roles in the progression of AD. In particular, Ca2+ plays a critical role in learning and memory processes [114,115,116,117,118], and Ca2+ dyshomeostasis is a pathological feature of AD and other neurodegenerative diseases [114,115,116,117,118]. The s1 receptor forms a Ca2+-sensitive chaperone complex with the binding immunoglobulin protein/glucose-regulated protein 78 (BiP/GRP78), and prolongs Ca2+-signaling from ER into mitochondria by stabilizing inositol 1,4,5-trisphosphate receptor (IP3R) at the MAM [74]. The s1 receptor participates in the regulation of intracellular Ca2+ migration and maintains homeostasis and protects cognitive function damage [119,120]. Research on the role of the s1 receptor in mediating mitochondrial function has found that the s1 receptor attenuates hippocampal dendrite formation through scavenging of free radicals, and protects cells from damage by mitochondria-derived reactive oxygen species (ROS) [121,122,123]. The ER stress sensor inositol-requiring enzyme 1 (IRE1) facilitates mitochondrion-ER-nucleus signaling for cellular survival via the s1 receptor chaperone [75,124].[/quote]

https://www.mdpi.com/1422-0067/24/15/12025